Zhejiang Hisun Pharmaceutical Hits Day High with Strong 3.37% Intraday Surge

Zhejiang Hisun Pharmaceutical Co., Ltd. has experienced a notable uptick in its stock performance, gaining 3.37% on March 24, 2026. The stock reached an intraday high of CNY 9.83, reflecting a positive shift in market sentiment. This performance stands in contrast to the China Shanghai Composite, which recorded a gain of 1.78% on the same day. Over the past year, Zhejiang Hisun has shown resilience, with a return of 15.26%, slightly outperforming the broader market index, which posted a return of 15.17%. However, the stock has faced challenges in the short term, with a weekly decline of 7.18% compared to the composite's drop of 4.16%. Financially, the company boasts a market capitalization of CNY 11,262 million and a price-to-earnings ratio of 25.00. Its return on equity stands at 6.78%, and it maintains a healthy debt-to-equity ratio of 0.25. The stock also offers a dividend yield of 2.25%, making it an attractive option for income-focused investors. Overall, Zhejiang Hisun's recent performance highlights its position within the pharmaceuticals and biotechnology sector.